TY - JOUR
T1 - Lack of an association between serum level of transforming growth factor beta -1 and stomach cancer risk in the JACC study.
AU - Yatsuya, Hiroshi
AU - Tamakoshi, Akiko
AU - Tamakoshi, Koji
AU - Hoshiyama, Yoshiharu
AU - Fujino, Yoshihisa
AU - Tokui, Noritaka
AU - Mizoue, Tetsuya
AU - Kikuchi, Shogo
AU - Sakata, Kiyomi
AU - Hayakawa, Norihiko
AU - Kondo, Takaaki
AU - Toyoshima, Hideaki
AU - Yoshimura, Takesumi
PY - 2005
Y1 - 2005
N2 - Alterations in the serum concentration of transforming growth factor beta-1 (TGFbeta1) have been observed in gastric cancer patients. No study, however, has ever examined the association between the serum TGFbeta1 level and stomach cancer prospectively. We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the JACC Study to assess whether serum level of total TGFbeta1 is associated with a subsequent risk of stomach cancer. The concentration of serum TGFbeta1 in previously collected blood samples was analyzed by ELISA for 209 individuals in whom a diagnosis of stomach cancer was documented, and for 409 controls matched with them for gender, age and study area. Baseline blood levels of TGFbeta1 were not related to the risk of stomach cancer in either men or women, a finding unchanged even after adjustment for potential confounders. The multivariate-adjusted odds ratio of stomach cancer in men and women was 1.10 (95% CI, 0.82 to 1.48) and 1.09 (95% CI, 0.80 to 1.48), respectively, for each increase of 1 SD in the TGFbeta1 value. In conclusion, serum TGFbeta1 levels were not associated with increased risks of subsequent stomach cancer.gene A52C polymorphism related to the metabolism of long-chain fatty acids and oxidized LDL in the etiology of colorectal cancer.
AB - Alterations in the serum concentration of transforming growth factor beta-1 (TGFbeta1) have been observed in gastric cancer patients. No study, however, has ever examined the association between the serum TGFbeta1 level and stomach cancer prospectively. We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the JACC Study to assess whether serum level of total TGFbeta1 is associated with a subsequent risk of stomach cancer. The concentration of serum TGFbeta1 in previously collected blood samples was analyzed by ELISA for 209 individuals in whom a diagnosis of stomach cancer was documented, and for 409 controls matched with them for gender, age and study area. Baseline blood levels of TGFbeta1 were not related to the risk of stomach cancer in either men or women, a finding unchanged even after adjustment for potential confounders. The multivariate-adjusted odds ratio of stomach cancer in men and women was 1.10 (95% CI, 0.82 to 1.48) and 1.09 (95% CI, 0.80 to 1.48), respectively, for each increase of 1 SD in the TGFbeta1 value. In conclusion, serum TGFbeta1 levels were not associated with increased risks of subsequent stomach cancer.gene A52C polymorphism related to the metabolism of long-chain fatty acids and oxidized LDL in the etiology of colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=24944465767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944465767&partnerID=8YFLogxK
M3 - Article
C2 - 16101328
AN - SCOPUS:24944465767
SN - 1513-7368
VL - 6
SP - 170
EP - 176
JO - Asian Pacific journal of cancer prevention : APJCP
JF - Asian Pacific journal of cancer prevention : APJCP
IS - 2
ER -
